Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Human Genome Sciences Rises on GSK Sale Rumors

By Pharmaceutical Processing | October 19, 2011

NEW YORK (AP) — Shares of Human Genome Sciences Inc. climbed Tuesday on a report saying Human Genome Sciences may be acquired by GlaxoSmithKline PLC, its partner on the lupus drug Benlysta.

THE SPARK: The Daily Mail, a British newspaper, said that U.K. drugmaker GlaxoSmithKline might buy Human Genome Sciences. The paper didn’t cite any people with knowledge of a possible deal, but said there was “revived speculation” of a bid by GlaxoSmithKline.

The companies are marketing Benlysta together in the U.S. and GlaxoSmithKline is in charge of marketing the drug in Europe. Human Genome Sciences, which is based in Rockville, Md., did not immediately respond to a request for comment.

THE BIG PICTURE: Benlysta is designed to treat flare-ups and pain caused by the autoimmune disease lupus. It is the first new drug approved to treat lupus in 50 years, and analysts have predicted that sales will reach billions of dollars a year. But so far, sales have been disappointing.

In September, a unit of the U.K.’s publicly funded National Health Service recommended that the NHS not cover Benlysta because its costs did not justify the expense. In the U.S., a patient’s first year of treatment with Benlysta costs $40,000, and after that, it costs $35,000 per year.

SHARE ACTION: The stock rose $1.23, or 10.9 percent, to $12.48 in afternoon trading. Human Genome Sciences shares reached a peak for the year at $30.15 on April 14, about a month after the Food and Drug Administration approved Benlysta. The stock fell to a 52-week low of $10.40 on Thursday.

 

 

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards